Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor of Musculoskeletal and Surgical Science, David Beard, has been awarded an Honorary Fellowship by the British Orthopaedic Association.

Horizontal portrait of David Beard

An Honorary Fellowship is the highest honour that the BOA (British Orthopaedic Association) can confer. It was awarded to Professor Beard in recognition of his outstanding contribution and achievements in research across the Trauma and Orthopaedic spectrum leading to improvements in patient care.

Professor Beard is one of the nominated Royal College of Surgeons (Eng) Surgical Trials chairs and Rosetrees Director of the Surgical Intervention Trials Unit (SITU-NDORMS) being responsible for a portfolio of surgical and complex intervention trials, many as co-applicant and some as Chief Investigator.

He is currently researching the introduction of robotic surgery in the NHS, surgical clinical trials methodology, including placebo control designs, and a host of musculoskeletal intervention efficacy studies. He is also involved in several international surgical trials and and supervises postgraduate students within NDORMS.

On being awarded the Honorary Fellowship, Professor Beard said;  

“I am very privileged and honoured to be given such a prestigious Fellowship by the BOA, especially in my core discipline, orthopaedic science. Like most personal awards the letters and certificate may point to a single name but it simply would not happen without the support and help from a set of first rate colleagues both in the Department and around the country.  To me it is very much a shared team award reflecting and recognising the success of orthopaedic/MSK research in Oxford (and the UK) over many years. Similar to everyone in NDORMS, I shall continue to do my very best research under the overall umbrella of improving healthcare, but it would give added satisfaction to see NDORMS remaining in the very top flight of those pursuing such an endeavour.” 

Similar stories

£1.2M to improve diagnosis of emergency spinal condition

The National Institute for Health and Care Research has awarded an Advanced Fellowship to Dr David Metcalfe to study the diagnosis of the spinal condition, cauda equina syndrome.

Professor Chris Lavy appointed to WHO technical advisory group

Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization’s (WHO) technical advisory group for integrated clinical care for a period of two years.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Gene variant links trigger finger and carpal tunnel syndrome

A new NDORMS study, published in The Lancet Rheumatology, has found a genetic variant that increases the risk of both carpal tunnel syndrome and trigger finger, and opens the door for new therapies that involve blocking the IGF-1 pathway.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

OCTRU collaboration boosts understanding of COVID vaccine response

Working with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).